RIMAG GROUP (02522) released its interim results, with revenue of 513 million yuan, a year-on-year increase of 9.8%.

RIMAG GROUP (02522) announced its interim results for the six months ending June 30, 2026, reporting revenue of 513 million yuan, a year-on-year increase of 9.8%. The loss attributable to shareholders was 13.891 million yuan, resulting in a loss per share of 0.036 yuan. During the reporting period, the Group's revenue increased year-on-year, primarily due to its efforts to seize opportunities in the digital transformation of the industry. It continued to build a digital medical imaging ecosystem, with growth in revenue driven by the scaling of empowerment solution services and digital services. Specifically, the Group has used empowerment solution services as a key approach to implement its various business strategies, consistently deepening its market presence and expanding its customer base across different levels of public hospitals and grassroots health institutions. This has allowed the Group to deeply explore the ongoing demand from existing healthcare institutions, directly driving continuous growth in the revenue of the empowerment solution services sector. Systematic progress has also been made in four key dimensions: data governance, asset monetization, AI products, and ecosystem synergy, leading to exponential growth in digital service revenue, which increased more than threefold compared to the same period in 2025, with commercial value accelerating to fruition.